CEP-28122 mesylate salt

• CAT Number: I005871
• Molecular Formula: C29H39ClN6O6S
• Molecular Weight: 635.17
• Purity: ≥95%
• Target: ALK
• Solubility: DMSO: ≥ 6.4 mg/mL, DMSO ＜ 9.2 mg/mL
• Storage: Store at -20°C
• IC50: 1.9 ± 0.5 nM
• IUPAC Name: (1S,2S,3R,4R)-3-[[5-chloro-2-[[(7S)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide;methanesulfonic acid
• InChI: InChI=1S/C28H35ClN6O3.CH4O3S/c1-37-25-20-8-7-19(35-10-12-38-13-11-35)6-4-16(20)5-9-22(25)32-28-31-15-21(29)27(34-28)33-24-18-3-2-17(14-18)23(24)26(30)36;1-5(2,3)4/h2-3,5,9,15,17-19,23-24H,4,6-8,10-14H2,1H3,(H2,30,36)(H2,31,32,33,34);1H3,(H,2,3,4)/t17-,18+,19+,23+,24-;/m1./s1
• InChIKey: PIIIZYXUYVVFSN-WWQCAQLDSA-N
• SMILES: COC1=C(C=CC2=C1CC[C@H](CC2)N3CCOCC3)NC4=NC=C(C(=N4)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl.CS(=O)(=O)O

CEP-28122 Mesylate Salt(CAT: I005871) is a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase (ALK), exhibiting an IC₅₀ of 1.9 ± 0.5 nM in enzyme-based time-resolved fluorescence (TRF) assays. By targeting ALK, CEP-28122 effectively disrupts aberrant signaling pathways involved in tumor cell proliferation and survival, making it a promising agent in the treatment of ALK-driven cancers, such as non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL). Its high selectivity and oral bioavailability position CEP-28122 Mesylate Salt as a valuable compound in Oncology research for developing targeted cancer therapies.